Predicting cetuximab accumulation in KRAS wild‐type and KRAS mutant colorectal cancer using (64)Cu‐labeled cetuximab positron emission tomography

Overexpression of epidermal growth factor receptor (EGFR) is common in colorectal cancer. However, cetuximab as an EGFR‐targeting drug is useful only for a subset of patients and currently no single predictor other than V‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status has...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Achmad, Arifudin, Hanaoka, Hirofumi, Yoshioka, Hiroki, Yamamoto, Shinji, Tominaga, Hideyuki, Araki, Takuya, Ohshima, Yasuhiro, Oriuchi, Noboru, Endo, Keigo
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2012
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7713619/
https://ncbi.nlm.nih.gov/pubmed/22126621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2011.02166.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky